FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
-------------	------	-------

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number: 3235-028									
Estimated average burden									
hours per response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* HEALY JAMES					2. Issuer Name and Ticker or Trading Symbol Coherus BioSciences, Inc. [CHRS]					(Ch	5. Relationship of Reporting Person(s) (Check all applicable) X Director 10			to Issu % Owi		
(Last)	`	irst) NVESTMENTS	(Middle) 5, INC.		3. Date of Earliest Transaction (Month/Day/Year) 01/07/2022						Officer below)	(give title		her (sp low)	pecify	
3000 SAND HILL ROAD, BLDG. 4, SUITE 250				0	4. If Amendment, Date of Original Filed (Month/Day/Year)						6. Individual or Joint/Group Filing (Check Applicable Line)					
(Street) MENLO	PARK C.	A	94025								- 1	X Form f	led by One liled by More			
(City)	(S	tate)	(Zip)													
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																
Date			?. Transacti Date Month/Day	Execution Date,		Code (Inst	Transaction Disposed Of (D) (Instr. 3, 2) Code (Instr. 5)			5. Amour Securitie Beneficia Owned F Reported	s ally following	6. Ownersh Form: Direc (D) or Indire (I) (Instr. 4)	t o	7. Nature of Indirect Beneficial Ownership		
						Code V	Amount	(A) or (D)	Price	Transact (Instr. 3 a	ion(s)		"	(Instr. 4)		
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																
1. Title of Derivative Security (Instr. 3)	tive Conversion Date Execution Date, or Exercise (Month/Day/Year) if any		Cod	ansaction of ode (Instr. Derivative		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	Owne Form Director Ind (I) (In	(D) irect	Beneficial Ownership (Instr. 4)		
				Cod	e V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares					
Stock Option (Right to Buy)	\$15.94	01/07/2022		A		27,000		(1)	01/07/2032	Common Stock	27,000	\$0.00	27,000	1)	

Explanation of Responses:

1. The underlying shares subject to the option vest and become exercisable as to 1/12th of the total number of shares subject to the option in successive, equal monthly installments measured from January 1, 2022, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.

/s/ McDavid Stilwell, as

Attorney-in-Fact for James I.

01/07/2022

Healy, M.D., Ph.D.

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.